DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Ipilimumab is an investigational drug.
There have been 426 clinical trials for Ipilimumab. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2013.
The most common disease conditions in clinical trials are Melanoma, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Bristol-Myers Squibb, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are one hundred and fifty-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Ipilimumab
|CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)||Huntsman Cancer Institute||Phase 1/Phase 2|
|CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)||OncoImmune, Inc.||Phase 1/Phase 2|
|Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors||National Cancer Institute (NCI)||Phase 2|
Top disease conditions for Ipilimumab
Top clinical trial sponsors for Ipilimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ipilimumab||See Pricing||Compositions and methods of tumor treatment utilizing nanoparticles||OP NANO CO., LTD. (Taipei, TW) TRENDMED CO., LTD. (Beitou Dist., Taipei, TW)||See Pricing|
|Ipilimumab||See Pricing||Histone deacetylase 6 inhibition for enhancing T-cell function during anti-tumor response and tumor-peptide vaccination||H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL)||See Pricing|
|Ipilimumab||See Pricing||Encapsulated agents and methods of making and using thereof||University of Georgia Research Foundation, Inc. (Athens, GA)||See Pricing|
|Ipilimumab||See Pricing||Method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor||Amgen Inc. (Thousand Oaks, CA)||See Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ipilimumab||European Patent Office||3256110||2035-02-13||See Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|